Surgical resection of non-small cell carcinoma after treatment for small cell carcinoma.

BACKGROUND Development of non-small cell lung carcinoma (NSCLC) in patients previously treated for small cell carcinoma (SCLC/NSCLC) is well described; however, little is known about clinical outcome. METHODS A single-institution 20-year review was performed. Patient characteristics and survival for SCLC/ NSCLC patients were compared with those for control patients matched for stage, resection, and previous malignancy. RESULTS One thousand four hundred four patients with small cell carcinoma were identified, and 29 underwent therapy for metachronous NSCLC: 11 of 29 patients underwent surgical resection, 10 of these 11 (90%) were stage I. Compared with surgically treated stage I NSCLC patients, SCLC/NSCLC patients were more likely to have squamous histology (70% versus 35%, p = 0.026); and subanatomic resection (90% versus 17.4%, p < 0.0005). The SCLC/NSCLC patients had significantly poorer survival when compared with stage I NSCLC patients undergoing any resection (24.53 versus 74.43 months, p = 0.003) and stage I NSCLC patients receiving wedge resection (24.53 versus 58.39 months, p = 0.006). Survival was similar to NSCLC patients with a history of previous treated extrathoracic solid malignancy. CONCLUSIONS Surgical resection for SCLC/NSCLC patients is feasible, but poorer prognosis is noted when compared with stage-matched control patients. Surgical candidates should be carefully chosen, and alternative local control modalities considered.

[1]  D. Ettinger,et al.  Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. , 1997, Journal of the National Cancer Institute.

[2]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[3]  P. Okunieff,et al.  Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Tucker,et al.  Smoking Cessation after Successful Treatment of Small-Cell Lung Cancer Is Associated with Fewer Smoking-related Second Primary Cancers , 1993, Annals of Internal Medicine.

[5]  E. Shaw,et al.  Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[7]  B. Johnson,et al.  Second lung cancers in patients after treatment for an initial lung cancer. , 1998, Journal of the National Cancer Institute.

[8]  R. Yesner Classification of lung-cancer histology. , 1985, The New England journal of medicine.

[9]  M. Lishner,et al.  Second primary malignancies following diagnosis of small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  市瀬 裕一 12) Swisher, Roth, Nemunaitis, et al. Adenovirusmediated p53 gene transfer in advanced nonsmall-cell lung cancer. J Natl Cancer Inst. 1999; 91: 763-71 , 2001 .

[11]  M E Burt,et al.  Incidence of local recurrence and second primary tumors in resected stage I lung cancer. , 1995, The Journal of thoracic and cardiovascular surgery.

[12]  N. Masuda,et al.  Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. , 1998, British Journal of Cancer.

[13]  S. Lippman,et al.  The incidence of second primary tumors in long-term survivors of small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  É. Quoix,et al.  Radiochimiothérapie optimisée pour le cancer bronchique non à petites cellules localement évolué , 1998 .

[15]  R. Yesner Small cell tumors of the lung. , 1983, The American journal of surgical pathology.

[16]  Z. Hao,et al.  p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy , 1997, Oncogene.

[17]  T. Hsu,et al.  DNA repair and mutagen sensitivity in patients with triple primary cancers. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.